“CEO Marc Beer and Renovia Announce Support of Recommendations by ACOG and WPSI “

When Marc Beer co-found Renovia in 2016, he was on the mission of developing digital therapeutic and diagnostic devices to treat pelvic floor disorders. Research sources reported a common disorder, known as urinary incontinence affects over 20 million women in the United States. Approximately 61 percent of those women under the age of 60 experience leakage which is treatable sometimes through exercising and strengthening the pelvic floor. Women’s Preventive Services Initiative (WPSI) and The American College of Obstetricians and Gynecologists (ACOG) released recommendations and opinions on the importance of urinary incontinence screening. Renovia is supporting the initiatives of the organizations to improve and maintain the health of women.


Renovia made the announcement in a press release on August 28th, 2018 of their support for urinary incontinence screening recommendations by ACOG and WPSI. As part of postpartum care for women, ACOG released its Committee Opinion-736 which recommends the screening for various pelvic floor disorders. ACOG leads national coalition, WPSI which released the first screening guidelines for detection and routine screening of all women including those in their adolescence. Women’s Preventive Services Initiative published the guidelines on August 14th to encourage early detection of urinary incontinence disorders and alternative treatments. Marc Beer and the Renovia team are dedicated to bringing awareness to millions of women and continuously supporting the initiatives of WPSI and The American College of Obstetricians and Gynecologists.


During the same year of supporting ACOG and WPSI, Marc Beer helped Renovia raise $42 million in Series B funds and venture debt. These funds are for developing and testing new products for therapeutic treatments and diagnostics. Marc and his partners received funding from healthcare investment firm, The Longwood Fund. Renovia is a med-tech company in Boston, Massachusetts and producer of FDA-approved device, Leva Pelvic Digital Health System. The device is for treating urinary incontinence and stress, and for strengthening the pelvic floor muscles through exercises.


Marc Beer serves as CEO and Chairman of Renovia for nearly three years with partners, Yolanda Lorie and Ramon Iglesias. He has 26 years of experience in the development and commercialization of biotechnology, diagnostics, pharmaceuticals, and a variety of devices. Before co-founding Renovia, Beer earned a bachelor’s degree from Miami University and joined Abbott Laboratories working in the sales and marketing. He left Abbot to serve as vice president of global marketing for Genzyme and later years later worked as CEO for Viacell. Learn more: https://www.crunchbase.com/person/marc-beer



Marc Beer set to revolutionize women’s healthcare through his MedTech startup

Marc Beer is the co-founder and CEO of Renovia; a biotechnology company focused on addressing medical problems facing women. Marc has been in the healthcare sector as an executive for over 25 years. March has dedicated most of his career towards the development of biotechnology and it’s commercialization. Renovia was founded by Marc and his business partners Yolanda Lorie and Ramon Iglesias who is currently the Managing Director in August 2016. Under the capable leadership of Marc, Renovia has grown to one of the most notable MedTech companies and successfully completed its Series A financing attracting notable healthcare venture capital funds. Before this venture, Marc worked as the Founding CEO of ViaCell and Founding Chairman of Good Star Genetics board of directors.


The women’s healthcare revolution


Recently, Marc Beer conducted a Series B financing campaign for his Renovia biotech company and successfully raised $32 million. He was also able to raise another $10 million as part of venture debt totalling his collection at $42 million. Marc plans to utilize these funds to help his company develop new products to address various medical issues related to pelvic floor disorders in women. This medical condition is known to affect at least 250 million women worldwide. Renovia, which is based in Boston is committed to developing diagnostic and therapeutic products that that can remedy pelvic floor disorders especially urinary incontinence.


A united front


During a press release announcing the collection of the funds, Marc Beer announced that his companies fight against this dreaded condition. He said that some of the company’s Series B investors had shown interest in uniting with them to help women globally manage pelvic floor disorders. Marc particularly pointed out the Longwood Fund as their partners in this united front against this condition.


The Renovia co-founder and CEO went ahead to state that this new investor will be very vital in the development of the second edition of their first product, Leva. The FDA approved the first edition of the Leva product in April, and Marc wants to make significant improvements to it on its second edition. The Longwood Fund’s long-term experience as a healthcare-focused investment firm will play a significant role in this according to Beer.


Cheaper healthcare


Beer went ahead to state that by Renovia working closely with the Longwood Fund, it will be possible for them to lower the cost of this healthcare for women across the globe. He stated that by the two companies combining their proprietary innovative sensor technologies, they could come up with affordable treatment options. Marc Beer said that his company planned to use its digital health platform to provide its customers with valuable data that will help them make informed decisions. Learn more: https://www.cnbc.com/video/2013/01/23/aegerion-ceo-on-promise-of-biopharma.html


The Work of Marc Beer

Marc Beer and his company Renovia Inc. recently made major news. The company is moving forward with plans to produce several new products for pelvic floor disorders. This comes as the company closes multiple million dollar deals including a thirty-two million dollar series B deal.


Renovia Inc. is a Boston-based medtech company that has made a name for itself by developing a variety of products that treat pelvic floor disorders. These disorders, which include urinary incontinence, affect more than two hundred and fifty million women across the world. Renovia is working together with the The Longwood Fund. This group got in early on the investing process along with New York-based Perceptive Advisors and Missouri-Based Ascension Ventures.


When speaking of the event, Marc Beer had lots of good things to say. “We are thrilled to have the support of this group of leading healthcare investors,” says Beer. Beer went on to explain these companies share the same vision to better diagnose, treat and improve the lives of women affected by these disorders. Learn more: https://ideamensch.com/marc-beer/


Marc Beer has built an impressive career as an entrepreneur. Beer is the CEO and nd Co-founder of Renovia Inc. He has more than two decades of experience in the pharmaceutical and biotechnology world. Beer has also spent time as the CEO of ViaCell. This biotech firm specializes in the development and preservation of stem cells. Under Beer’s leadership this company has grown to more than three hundred employees. Other notable achievements during Beer’s career including being chairman of the directors’ board for Good Start Genetics Compensation Committee and founding chairman of the compensation committee of Minerva Neurosciences Inc Audit Committee.


Marc Beer believes his success is a result of his daily schedule. His typical week is focused on talent acquisition, organizational structure and process around operations. Beer believes if you have the right talent you can build success in healthcare. Beer believes he has put a good leadership team in place at Renovia and this is a big part of their early success. Beer’s approach is to build a successful leadership team and keep them focus on the overall long term vision